A Phase I Trial of Combined immunotherapy with nivolumab and interferon-beta in Patients with advanced melanoma.

A Phase I Trial of Combined immunotherapy with nivolumab and interferon-beta in Patients with advanced melanoma. - A Phase I Trial of immunotherapy with nivolumab and interferon-beta in melanoma patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020222

Enrollment

Registered

2015-12-17

Start date

2016-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced melanoma

Interventions

A combination immunotherapy with nivolumab (2mg/ kg) and IFN-beta (1 million U, 2 million U or 3 million U).At day 0, IFNb is administered in combination with nivolumab. Then, according to the convent

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: unresectable advanced melanoma

Exclusion criteria

Exclusion criteria: hypersensitibity against nivolumab

Design outcomes

Primary

Measure	Time frame
Adverse event Maximum tolerated dose (MTD) At 6 weeks, we assess the primary outcomes and will observe during 6 months.	—

Countries

Japan

Contacts

Public ContactTaku Fujimura

Tohoku University Graduate School of Medicine Department of Dermatology

tfujimura1@mac.com022-717-7271

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026